LigaChem Biosciences Inc. (KOSDAQ:141080)
178,200
+600 (0.34%)
Nov 21, 2025, 3:30 PM KST
LigaChem Biosciences Revenue
LigaChem Biosciences had revenue of 32.62B KRW in the quarter ending June 30, 2025, with 6.06% growth. This brings the company's revenue in the last twelve months to 148.28B, up 94.55% year-over-year. In the year 2024, LigaChem Biosciences had annual revenue of 125.90B with 268.71% growth.
Revenue (ttm)
148.28B
Revenue Growth
+94.55%
P/S Ratio
43.76
Revenue / Employee
872.24M
Employees
170
Market Cap
6.49T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 125.90B | 91.75B | 268.71% |
| Dec 31, 2023 | 34.15B | 733.60M | 2.20% |
| Dec 31, 2022 | 33.41B | 1.26B | 3.90% |
| Dec 31, 2021 | 32.16B | -25.34B | -44.07% |
| Dec 31, 2019 | 57.50B | 32.26B | 127.81% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 675.41B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |